$16.14 0.04 (0.25%)
16:39 EDT MYL Stock Quote Delayed 30 Minutes
Previous Close $16.18
Market Cap 8.64B
PE Ratio -
Volume (Avg. Vol.) 4.35M
Day's Range 16.05 - 16.55
52-Week Range 12.75 - 23.11
Dividend & Yield N/A (N/A)
MYL Stock Predictions, Articles, and Mylan News
- From InvestorPlace
- From the Web
Mylan stock is getting smashed after its fourth-quarter earnings results and full-year outlook. MYL stock could still go lower, though.
As Goldman Sachs moves away from the strong balance sheet investing strategy, here are 6 new stocks to buy.
Abbott is about to report another quarter to cap 2018's strong annual performance. ABT stock also offers a dividend for income investors.
Biotech stocks are likely to continue to be volatile in December, but that may create unique buying opportunities.
Mylan stock jumped ahead following quarterly earnings that impressed investors. Management will continue doing better than expected.
Earnings set to the tone for Toyota, CVS Health, Eli Lilly and Mylan as our top stock trades. But midterms will set the tone for the week.
Mylan stock (MYL) is soaring more than 7% after hours Monday as the. company's third-quarter earnings doubled and beat Wall Street estimates.
In the latest EpiPen news, the Food and Drug Administration (FDA) has extended the expiration dates of the allergy medication due to a shortage of EpiPens.
An EpiPen shortage has parents worried as the school season starts back up across the U.S., but there are other options.
MYL stock has been stuck in a downtrend for three-plus years, and nothing about second-quarter numbers imply that this downtrend is ending soon.
Thinking about buying Mylan stock? These are the four risks that you need to understand before taking the plunge
The Food and Drug Administration (FDA) announced a list of drug makers that have tried to block generic drugs in its new shame list. Here they are.
Mylan NV (MYL) stock was up on Wednesday following the release of its earnings report for the first quarter of the year.
MYL stock's forward P/E multiples don't reflect the growth potential for the Mylan NV. EpiPen demand and biosimilars will soon give the company a revenue lift.
Once all the Mylan headlines start to sink in, investor perspective could change. That would then move MYL stock that hasn't gone anywhere since February.
RVNC has an edge with its formulation of Botox: it lasts longer. Given the little innovation in the botulinim toxin market, Revance has a real chance to succeed.
Negative public perception peaked for Mylan NV last year, but that's now history. With strong, positive cash flow in 2018 and new products lined up for MYL, value investors should take another look at Mylan stock.
Thinking about buying Mylan stock? You may not want to just yet. It's toying with a support line that, if it snaps, could open the selling floodgates.
Despite a wealth of bullish news since the beginning of March, MYL stock remains capped by this key trendline ... and it will send Mylan shares lower as a result.
Amazon (AMZN) explores online pharmaceuticals with Novartis AG (NVS), Nutanix (NTNX) and Zumiez (ZUMZ) report on their quarterly earnings.
From Simply Wall St
While not a mind-blowing move, it is good to see that the Insignia Systems, Inc. (NASDAQ:ISIG) share price has gained 27% in the last three months. But don’t envy holders<div><a class="permalink" href="https://simplywall.st/stocks/us/media/nasdaq-isig/insignia-systems/news/imagine-owning-insignia-systems-nasdaqisig-and-trying-to-stomach-the-72-share-price-drop/">Read More...</a></div>
From Simply Wall St
In 2016, Kristine Glancy was appointed CEO of Insignia Systems, Inc. (NASDAQ:ISIG). This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Then we’ll<div><a class="permalink" href="https://simplywall.st/stocks/us/media/nasdaq-isig/insignia-systems/news/does-insignia-systems-inc-s-nasdaqisig-ceo-pay-reflect-performance-2/">Read More...</a></div>
Navellier RatingsPowered by Portfolio Grader